^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    itraconazole

    Company:
    Generic mfg.
    Drug class:
    CYP51A1 inhibitor
    Related drugs:
    22h
    Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions With the Antibody-Drug Conjugate Trastuzumab Deruxtecan. (PubMed, CPT Pharmacometrics Syst Pharmacol)
    The topoisomerase I inhibitor payload (DXd) released from the human epidermal growth factor receptor 2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) is eliminated by hepatic uptake via OATP1B1/3, metabolism by CYP3A, biliary excretion via P-glycoprotein and breast cancer resistance protein, and urinary excretion. DDIs with ritonavir and itraconazole simulated by the PBPK model reproduced the clinical DDI study results, indicating that the impact of concomitant medications was not clinically meaningful. These findings suggest that this model may potentially be used for DDI evaluation of future DXd-containing ADCs, aiding in the prediction of DDIs under different scenarios and in specific populations.
    PK/PD data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • itraconazole • ritonavir
    7d
    SHR-A1811-105: Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer (clinicaltrials.gov)
    P1, N=17, Completed, Jiangsu HengRui Medicine Co., Ltd. | N=32 --> 17 | Trial completion date: Aug 2026 --> Oct 2025 | Trial primary completion date: Jun 2025 --> Oct 2025 | Recruiting --> Completed
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    trastuzumab rezetecan (SHR-A1811) • itraconazole • ritonavir
    8d
    Drug Interaction and Food Effect Study of CS0159 (clinicaltrials.gov)
    P1, N=32, Completed, Cascade Pharmaceuticals, Inc | Trial primary completion date: Feb 2027 --> Mar 2026 | Not yet recruiting --> Completed | Trial completion date: Feb 2027 --> Apr 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    itraconazole • rifampicin
    9d
    QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P1 trial
    |
    Nubeqa (darolutamide) • itraconazole • MHB088C • rifampicin
    13d
    Clinical characteristics and long-term prognosis of talaromycosis in children with novel and reported inborn errors of immunity. (PubMed, Front Immunol)
    Voriconazole and itraconazole are commonly used for maintenance therapy. Treatment and long-time management remain a challenge. Besides, long lasting anti-fungal and immune boosting therapy may be necessary, while HSCT intervention could provide potential benefits.
    Observational data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PLCG2 (Phospholipase C Gamma 2) • IL7R (Interleukin 7 Receptor) • STAT1 (Signal Transducer And Activator Of Transcription 1) • CD40LG (CD40 ligand) • DOCK8 (Dedicator Of Cytokinesis 8) • CARD9 (Caspase Recruitment Domain Family Member 9) • IL2RG (Interleukin 2 Receptor Subunit Gamma)
    |
    itraconazole
    13d
    Itraconazole Therapy In Bronchiectasis With Airway Mold (clinicaltrials.gov)
    P4, N=30, Recruiting, Mayo Clinic | Initiation date: Mar 2026 --> Jun 2026
    Trial initiation date
    |
    itraconazole
    16d
    A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017) (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    prednisone • itraconazole • opevesostat (MK-5684)
    16d
    Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis (clinicaltrials.gov)
    P1, N=165, Active, not recruiting, Vertex Pharmaceuticals Incorporated | Recruiting --> Active, not recruiting | N=255 --> 165
    Enrollment closed • Enrollment change
    |
    itraconazole • midazolam hydrochloride
    20d
    Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole (clinicaltrials.gov)
    P1, N=28, Completed, Acesion Pharma | Active, not recruiting --> Completed
    Trial completion
    |
    itraconazole
    22d
    A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=12, Recruiting, AbbVie
    New P1 trial
    |
    itraconazole
    23d
    Clinical Features and Diagnostic Challenges of Talaromyces marneffei Infection in Non-Endemic Regions: A 6-Case Study Highlighting NGS and Tailored Antifungal Therapy. (PubMed, Infect Drug Resist)
    Treatment was individualized: severe cases received extended amphotericin B lipid complex (ABLC) (cumulative dose up to 31.8g in case1) induction followed by azole maintenance; milder cases received oral itraconazole alone...NGS was essential for early detection. Individualized antifungal therapy-tailored to immune status and disease severity achieved favorable outcomes, underscoring the importance of personalized treatment strategies.
    Journal • Next-generation sequencing
    |
    CD4 (CD4 Molecule)
    |
    itraconazole
    24d
    A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants (clinicaltrials.gov)
    P1, N=14, Not yet recruiting, Eli Lilly and Company
    New P1 trial
    |
    itraconazole